Literature DB >> 3172117

Laxity and rupture of the patellar tendon in systemic lupus erythematosus. Association with secondary hyperparathyroidism.

S M Babini1, A Arturi, J C Marcos, J C Babini, A M Iniguez, O G Morteo.   

Abstract

We describe a patient with systemic lupus erythematosus, chronic renal failure and secondary hyperparathyroidism who developed laxity and elongation of the patellar tendon, followed by its rupture one year later. Hydroxyapatite and urate crystals were identified from the chalky material surrounding the patellar tendon observed at surgery. These findings suggest that tendon laxity and elongation could possibly be detected before its rupture and that secondary hyperparathyroidism could be considered as another causative factor of tendon damage in patients with systemic lupus erythematosus.

Entities:  

Mesh:

Year:  1988        PMID: 3172117

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Jaccoud's arthropathy of the hands in overlap syndrome.

Authors:  J G Paredes; M A Lazaro; G Citera; S Da Representacao; J A Maldonado Cocco
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

2.  Jaccoud's arthropathy in knees in systemic lupus erythematosus.

Authors:  M De la Sota; J A Maldonado Cocco
Journal:  Clin Rheumatol       Date:  1989-09       Impact factor: 2.980

Review 3.  Traumatic bilateral concurrent patellar tendon rupture: an alterative fixation method.

Authors:  Hok-Ming Ho; Wai-Keung Edison Lee
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2003-02-07       Impact factor: 4.342

4.  Loss of bone mineral density in premenopausal women with systemic lupus erythematosus.

Authors:  F Formiga; I Moga; J M Nolla; M Pac; F Mitjavila; D Roig-Escofet
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

5.  Metacarpal bone mass in systemic lupus erythematosus.

Authors:  A A Kalla; T J van Wyk Kotze; O L Meyers
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.